scholarly article | Q13442814 |
P356 | DOI | 10.1111/ALL.13082 |
P698 | PubMed publication ID | 27859399 |
P50 | author | Peter Bradding | Q41855963 |
Clair Barber | Q57329545 | ||
Roopesh Singh Gangwar | Q60327939 | ||
P2093 | author name string | S Holgate | |
A Chauhan | |||
P Howarth | |||
F Levi-Schaffer | |||
M Seaf | |||
Y Minai-Fleminger | |||
R Eliashar | |||
N Berkman | |||
A Shikotra | |||
A Gutgold | |||
P2860 | cites work | sCD48 is anti-inflammatory in Staphylococcus aureus Enterotoxin B-induced eosinophilic inflammation. | Q40032051 |
Polymorphisms related to ORMDL3 are associated with asthma susceptibility, alterations in transcriptional regulation of ORMDL3, and changes in TH2 cytokine levels. | Q40990818 | ||
Allergic host defences | Q41190858 | ||
The CD48 receptor mediates Staphylococcus aureus human and murine eosinophil activation | Q41726277 | ||
Human mast cell activation by Staphylococcus aureus: interleukin-8 and tumor necrosis factor alpha release and the role of Toll-like receptor 2 and CD48 molecules | Q42755341 | ||
2B4 (CD244) is expressed and functional on human eosinophils | Q45195916 | ||
Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines | Q28253247 | ||
Detection of a soluble form of the leukocyte surface antigen CD48 in plasma and its elevation in patients with lymphoid leukemias and arthritis | Q28258148 | ||
Mast cell activation by Mycobacterium tuberculosis: mediator release and role of CD48 | Q28574579 | ||
ORMDL3 promotes eosinophil trafficking and activation via regulation of integrins and CD48. | Q30573228 | ||
Molecular dissection of 2B4 signaling: implications for signal transduction by SLAM-related receptors | Q34345732 | ||
Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease | Q34832426 | ||
Asthma and allergic inflammation | Q35099497 | ||
CD48 is critically involved in allergic eosinophilic airway inflammation | Q35855225 | ||
Asthma control or severity: that is the question | Q36734990 | ||
Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients | Q36765753 | ||
Assessment of asthma control and its impact on optimal treatment strategy | Q36825049 | ||
Roles of CD48 in regulating immunity and tolerance | Q36883146 | ||
Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1 | Q37056664 | ||
Mast cells and eosinophils: the two key effector cells in allergic inflammation | Q37480813 | ||
CD48: A co-stimulatory receptor of immunity | Q37787551 | ||
Targeted therapy of bronchitis in obstructive airway diseases | Q38120928 | ||
Molecular targets on mast cells and basophils for novel therapies | Q38207295 | ||
Mast cells in asthma--state of the art. | Q38633155 | ||
'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. | Q38661772 | ||
P433 | issue | 6 | |
P921 | main subject | asthma | Q35869 |
P304 | page(s) | 888-895 | |
P577 | publication date | 2016-12-01 | |
P1433 | published in | Allergy | Q2699825 |
P1476 | title | CD48 on blood leukocytes and in serum of asthma patients varies with severity | |
P478 | volume | 72 |
Q42736759 | Asthma Biomarkers: Do They Bring Precision Medicine Closer to the Clinic? |
Q33785627 | Eosinophil Activation Status in Separate Compartments and Association with Asthma |
Q57300304 | Evaluation of Soluble CD48 Levels in Patients with Allergic and Nonallergic Asthma in Relation to Markers of Type 2 and Non-Type 2 Immunity: An Observational Study |
Q59332892 | Highlights and recent developments in airway diseases in EAACI journals (2017) |
Q50068947 | Human eosinophils and mast cells: Birds of a feather flock together |
Q64078040 | Subversion of natural killer cell responses by a cytomegalovirus-encoded soluble CD48 decoy receptor |
Search more.